Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib plus Erlotinib in EGFR-mutated NSCLC
NCT02355431Phase 2Withdrawn
- Sponsor
- Incyte
- Start
- Dec 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of itacitinib in non-small cell lung cancer (NSCLC), sponsored by Incyte. Planned start Dec 2014; status: withdrawn.
02
Drugs
itacitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02355431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02355431.